ExploreWatchlistsPricing
  1. US-listed companies
  2. BRAINSTORM CELL THERAPEUTICS INC.
  3. Financials
  4. Cash and cash equivalents

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Market cap
$11.03M
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 20250-25.61%
Dec 31, 20240-75.02%
Dec 31, 20231+92.36%
Dec 31, 20221-95.91%
Dec 31, 202119-50.15%
Dec 31, 202038+6957.65%
Dec 31, 20191-43.10%
Dec 31, 20181-62.06%
Dec 31, 20172+353.93%
Dec 31, 20161+27.80%
Dec 31, 20150-89.93%
Dec 31, 20144+21.35%
Dec 31, 20134+82.16%
Dec 31, 20112

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat